DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B | Real-time Bid/Ask 11:18:48 2024-07-03 EDT | ||
| 87.82 EUR / 87.87 EUR | -0.94% |
|
| Current month | -0.12% | ||
| 1 month | +2.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 88.3 | -0.43% |
| 24-07-02 | 88.68 | -0.30% |
| 24-07-01 | 88.95 | +0.18% |
| 24-06-28 | 88.79 | -0.10% |
| 24-06-27 | 88.88 | -0.20% |
Delayed Quote Börse Stuttgart
Last update July 03, 2024 at 06:36 am
More quotesStatic data
| Product type | Discount-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG1C9T |
| ISIN | DE000MG1C9T4 |
| Date issued | 2024-04-02 |
| Maturity | 2025-03-21 (261 Days) |
| Parity | 1 : 1 |
| Emission price | 85.55 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 89.06 € |
|---|---|
| Lowest since issue | 83.74 € |
| Spread | 0.06 € |
| Spread % | 0.07% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Certificates
- Certificat
